KLK3 and prostate carcinoma: In phase I clinical trials, ARV-110 reportedly showed promising activity in first line in patients with metastatic desmoplasia-resistant prostate cancer (mCRPC), with prostate specific antigen (PSA) reductions of more than 50% at doses greater than 280 mg (192).